Cancer Researchers Report Encouraging Early Results for mRNA Vaccine Therapies

In February 2026, when Moderna published its latest cancer treatment results, the paper's main text did not use the word "vaccine" once. The term appeared only in footnotes, buried in citations of older patents and papers [1]. The quiet semantic retreat — from "personalized cancer vaccine" to "individualized neoantigen therapy" — captures the strange moment facing one of oncology's most promising frontiers: a technology producing the best clinical data in its history while operating under the worst political conditions it has ever faced.

The Numbers That Have Oncologists Paying Attention

The headline trial is KEYNOTE-942, a Phase IIb study run by Moderna and Merck testing mRNA-4157 (now branded V940) combined with the checkpoint inhibitor pembrolizumab (Keytruda) in patients with resected high-risk melanoma. Five-year follow-up data show the combination reduced the risk of recurrence or death by 49% compared to Keytruda alone [2]. At the two-and-a-half-year mark, overall survival stood at 96% for the combination arm versus 90.2% for Keytruda monotherapy [3].

Source: Moderna/Merck KEYNOTE-942 Trial

Data as of Jan 1, 2026CSV

These numbers matter because the comparator is not a placebo — it is the current standard of care. Keytruda alone is already a potent drug. Adding a personalized mRNA vaccine on top of it produced a statistically significant additional benefit, which is what earned the combination FDA Breakthrough Therapy Designation in 2023 and EMA PRIME scheme recognition [4][5].

In a different cancer entirely, results from Memorial Sloan Kettering's Phase I pancreatic cancer trial are drawing attention for different reasons. Of 16 patients who received a personalized mRNA vaccine manufactured by BioNTech, eight mounted a measurable immune response. Among those eight responders, seven (87.5%) were still alive four to six years after surgery [6]. For a cancer with a five-year survival rate of roughly 13%, those numbers are striking. The CD8+ T cells — the immune system's cancer-killing cells — persisted for up to six years with no signs of decline [6]. A Phase II trial is now recruiting globally.

BioNTech has its own melanoma program. In July 2024, the company reported positive Phase II results for BNT111 combined with cemiplimab (Libtayo), showing an 18% overall response rate in patients whose cancer had already stopped responding to PD-1 inhibitors — a notoriously difficult population to treat [7].

Where the Trials Stand

More than 120 mRNA cancer vaccine trials are currently active worldwide, spanning melanoma, non-small cell lung cancer, pancreatic, colorectal, head and neck, prostate, and renal cancers [8]. The pipeline is heavily weighted toward early-stage work: 68 trials in Phase I, 32 in Phase I/II, and 18 in Phase II. Only four have reached Phase III, and three more are in transitional Phase II/III designs [8].

Source: ClinicalTrials.gov / Cromos Pharma

Data as of Apr 1, 2026CSV

Moderna's mRNA-4157 is the furthest along commercially. The melanoma Phase III program is actively enrolling, and two additional Phase III studies in non-small cell lung cancer are underway [9]. BioNTech is running late-stage trials with BNT113 in HPV-positive head and neck cancer, alongside earlier-stage work in colon, pancreatic, and lung cancers [7]. In August 2025, BioNTech announced plans to acquire CureVac following a patent dispute settlement, a deal the company said would strengthen its mRNA manufacturing and commercialization capabilities [9].

Moderna has committed approximately $25 billion in research and development spending from 2024 to 2028, with oncology as a major focus [9]. Regulatory submissions for the melanoma indication are anticipated in 2026, with commercial approval — if the Phase III data hold — projected after 2029 [8].

A Year of Political Headwinds

The clinical momentum has unfolded against an unusually hostile political backdrop. In the first weeks of the second Trump administration, U.S. cancer research was thrown into turmoil as federal grants were terminated and restructured en masse [10]. In March 2025, NIH acting director Matthew Memoli sent a letter asking that all grants, collaborations, or contracts involving mRNA be flagged for review by Robert F. Kennedy Jr., the Secretary of Health and Human Services [10].

The financial damage was concrete. The National Cancer Institute absorbed a 31% funding reduction in the first three months of 2025 [10]. In May 2025, the White House proposed cutting NCI funding by more than 40% [11]. In August, HHS canceled nearly $500 million in BARDA contracts supporting mRNA vaccine development — primarily targeting infectious disease programs, but sending shockwaves through the oncology research community that depends on the same technology platform [11][12].

NIH overhead reimbursement rates were slashed from the historical 50–60% range down to 15%, squeezing academic laboratories that run translational cancer research [10]. "This is an operation. We have to pay salaries; we have to buy food for the animals," Miriam Merad, a cancer immunologist at the Icahn School of Medicine at Mount Sinai, told Scientific American [10]. Her institution reduced postdoctoral hires; the medical school cut its incoming class size.

Kennedy also dismissed all 17 members of the Advisory Committee on Immunization Practices and replaced them with individuals who have expressed skepticism toward vaccines [10]. While ACIP primarily advises on preventive vaccines, researchers warned that the broader anti-mRNA posture could chill investment and trial enrollment for cancer applications.

The Naming Problem

The political environment has created a vocabulary crisis. Moderna stopped formally calling its cancer product a "vaccine" in 2023, rebranding it as "individualized neoantigen therapy" (INT) [1]. The stated rationale was that the product treats existing cancer rather than preventing it. But as MIT Technology Review reported in April 2026, the unstated goal was to distance the therapy from vaccine fearmongering amplified by senior U.S. officials [1].

Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute, who has enrolled patients in Moderna's trials, said that mistrust of mRNA vaccines since the pandemic has at times made it harder to recruit participants [13]. Some oncologists report that patients decline potentially beneficial cancer treatment because the word "vaccine" triggers suspicion rooted in COVID-era misinformation [14]. The false "turbo cancer" narrative — the debunked claim that COVID-19 mRNA vaccines cause aggressive cancers — continues to circulate online [14].

The Case for Skepticism

Even setting politics aside, there are substantive scientific reasons for caution. Oncology trials have a historically brutal attrition rate: roughly 95% of cancer drugs that enter Phase I testing never reach approval [15]. "Encouraging early results" have preceded many expensive disappointments in this field.

Several specific concerns apply to mRNA cancer vaccines. First, the most advanced data — the KEYNOTE-942 melanoma trial — used recurrence-free survival as its primary endpoint, not overall survival. Recurrence-free survival is a surrogate endpoint that does not always predict whether patients ultimately live longer [15]. Second, the trial enrolled patients with resected (surgically removed) high-risk melanoma, meaning the vaccine was tested in an adjuvant setting where patients had no measurable disease. Whether mRNA vaccines can shrink existing tumors at scale — the harder test — remains largely unproven in large trials.

Third, the pancreatic cancer data, while remarkable, come from just 16 patients. In oncology, small Phase I trials routinely produce response rates that collapse in larger studies as the patient population broadens. The 50% immune response rate in the MSK trial may not hold when the therapy is tested in hundreds of patients with more diverse tumor profiles and prior treatment histories [6].

Fourth, checkpoint inhibitor combinations have a long history of looking promising in early trials and then failing to show benefit in Phase III. The cancer vaccine field specifically carries scars: Dendreon's Provenge (sipuleucel-T), approved for prostate cancer in 2010, showed a modest four-month survival benefit but struggled commercially and the company went bankrupt [16].

The Manufacturing and Cost Problem

Personalized neoantigen vaccines are, by definition, bespoke. Each dose is manufactured for a single patient based on genomic sequencing of that individual's tumor. The process involves sequencing the tumor, identifying up to 20 high-probability neoantigens (mutations unique to the cancer), designing an mRNA construct, and manufacturing it — currently within two to four weeks [6][17].

This creates several structural challenges. Manufacturing costs are high: Provenge, the only personalized cancer vaccine precedent, launched at approximately $93,000 per course [16]. Personalized mRNA vaccines are expected to cost in a similar range or higher, though exact pricing has not been disclosed for products still in trials. For context, checkpoint inhibitors like pembrolizumab cost approximately $150,000–$200,000 per year, and the mRNA vaccine would be administered on top of that existing cost [16].

Scalability is a genuine bottleneck. Each vaccine requires individualized tumor profiling, specialized manufacturing, and cold-chain logistics. BioNTech manufactured the pancreatic cancer vaccines at its facility in Germany for the MSK trial — a model that works for 16 patients but faces questions at population scale [6]. The UK's National Health Service has partnered with Moderna with a goal of enrolling 10,000 cancer patients by 2030, backed by plans for manufacturing capacity of 250 million vaccines annually [10]. Whether that capacity will materialize, and at what cost, remains to be seen.

Equitable access is a downstream concern. Personalized vaccines require genomic sequencing infrastructure, bioinformatics analysis, and specialty pharmacy networks that are concentrated in wealthy countries and major academic medical centers. In the U.S. alone, fewer than 200 CPT billing codes exist for approximately 70,000 genetic tests, creating reimbursement friction even before the vaccine itself is priced [18]. Among clinical genomic sequencing cases studied, preauthorization was required in most cases but reimbursement was ultimately achieved in only 50% [18].

The Regulatory Landscape

The FDA granted Breakthrough Therapy Designation to mRNA-4157/V940 combined with pembrolizumab in 2023, based on the Phase IIb KEYNOTE-942 data [4]. This designation does not lower the evidentiary bar for approval but provides more frequent consultation with the agency and can accelerate the review timeline. The EMA granted parallel PRIME scheme recognition for the European pathway [5].

In 2024, the FDA released comprehensive guidance for therapeutic cancer vaccines, establishing clearer expectations for clinical trial design and endpoints [8]. The standard pathway remains traditional oncology drug approval, which typically requires at least one adequate and well-controlled Phase III trial demonstrating clinical benefit. Accelerated approval based on surrogate endpoints is possible but would require post-marketing confirmatory studies.

The current political environment adds uncertainty. The same administration that granted Breakthrough Therapy Designation under the FDA's career staff has an HHS leadership publicly skeptical of mRNA technology. Whether this skepticism will translate into regulatory friction — slower reviews, additional data requirements, or reluctance to grant accelerated approval — is an open question that industry executives and researchers are watching closely [12].

The Research Ecosystem

Academic research output on mRNA cancer vaccines surged from roughly 3,900 papers in 2019 to nearly 15,900 in 2023, before declining to approximately 11,800 in 2025 [19]. The 2025 decline reflects, in part, the chilling effect of federal funding uncertainty on new research proposals.

Source: OpenAlex

Data as of Jan 1, 2026CSV

Despite the funding pressures, the global trial infrastructure continues to expand. Memorial Sloan Kettering's Phase II pancreatic cancer trial is recruiting internationally [6]. Moderna's Phase III melanoma and lung cancer studies are enrolling across multiple countries. BioNTech initiated global trials for BNT116 in non-small cell lung cancer in August 2024 [9]. The geographic diversification partly insulates the field from U.S.-specific political risks, though American institutions remain central to the research enterprise.

Patient advocacy groups and health systems are beginning to plan for a post-approval world. The NHS partnership with Moderna represents the most concrete example of a national health system preparing manufacturing and access infrastructure in advance [10]. In the U.S., the reimbursement landscape remains underdeveloped: outcome-based payment agreements and staged payment models have been proposed to manage the concentrated upfront costs of personalized therapies, but no framework has been finalized [16].

What Happens Next

The field's near-term trajectory hinges on Phase III results. Moderna's KEYNOTE-942 Phase III melanoma data will be the first large-scale test of whether the Phase IIb signal holds in a broader, more diverse patient population. The lung cancer Phase III studies will test whether the approach generalizes beyond melanoma. Both readouts are expected within the next two to three years.

If the Phase III data confirm the earlier results, regulatory submissions could follow in 2026–2027, with potential commercial availability by 2028–2029 for the melanoma indication [8][10]. If they do not — if the historically high failure rate of oncology trials claims another promising candidate — the field will face a painful recalibration of expectations and investment.

In the meantime, the tension between scientific progress and political headwinds shows no sign of resolving. The technology that produced some of the fastest-developed vaccines in history during the COVID-19 pandemic is now being applied to one of medicine's hardest problems. The early data are genuinely encouraging. Whether they survive contact with Phase III reality, political interference, and the brutal economics of personalized medicine will determine whether mRNA cancer vaccines join the small pantheon of treatments that actually changed oncology — or become another chapter in its long history of dashed hopes.